Market Research Report: Amgen Inc.
Company Overview
Name
Amgen Inc.
Mission of the Company
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.
Founded
Amgen was founded in 1980.
Founders
No information is available.
Key People
- Sandra Rodriguez-Toledo, Vice President, Site Operations at Amgen Ohio
- Murielle Véniant-Ellison, leading Obesity Research initiatives at Amgen
Headquarters
No information is available on the exact location of the headquarters.
Number of Employees
No information is available.
Revenue
No information is available.
What the Company is Known For
Amgen is known for its pioneering work in the biotechnology industry, particularly for establishing itself as a leader in biologic medicines. They have been instrumental in developing therapies for cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. Amgen has a global presence in approximately 100 countries and ranks among the 30 companies that comprise the Dow Jones Industrial Average and the Nasdaq-100 Index.
Products
Product Offerings
1. Actimmune:
- Treats chronic granulomatous disease.
2. Aimovig:
- Migraine prevention.
3. Amjevita:
- A biosimilar for adalimumab, used in inflammatory diseases.
4. Aranesp:
- Anemia treatment associated with kidney failure or chemotherapy.
5. Avsola:
- A biosimilar to infliximab for autoimmune diseases.
6. Blincyto:
- Used for leukemia treatment.
7. Corlanor:
- Chronic heart failure treatment.
8. Enbrel:
- Used in treating autoimmune diseases like rheumatoid arthritis and plaque psoriasis.
9. Epogen:
- Treats anemia associated with chronic kidney disease.
High-level Description and Key Features
- Actimmune: Enhances the immune system function to prevent infections.
- Aimovig: It functions by blocking the calcitonin gene-related peptide receptor, a target in migraine therapy.
- Amjevita & Avsola: These are biosimilars, encouraged by Amgen’s longevity and expertise in biotech, mirroring their original branded counterparts.
- Blincyto: Targets specific leukemia cell markers, facilitating tailored therapy for patients.
- Enbrel: A TNF blocker that is key in reducing inflammation and is vital for long-term treatment plans in chronic conditions.
Recent Developments
Recent Developments in the Company
- In 2024, Rasmus Højgaard won the Amgen Irish Open, and over £200,000 was raised for Make-A-Wish Ireland, highlighting Amgen’s ongoing community and charitable involvement.
- Leveraging biomarkers and new modalities in oncology for new cancer treatments, especially aiming at the root causes.
- Hosted several cultural and inclusive initiatives like celebrating Hispanic Heritage Month and National Disability Employment Awareness Month.
- Sandra Rodriguez-Toledo was inducted into the Women in Manufacturing Hall of Fame.
New Products Launched
No information is available.
New Features Added to Existing Products
No specific feature updates for existing products are documented.
New Partnerships
No information is available regarding new partnerships.
Conclusion
Amgen remains a frontrunner in the biotechnology industry due to its innovative approaches in drug development, commitment to diversity and inclusion, and community involvement through charitable events. Their extensive range of products continues to meet global health needs while consistently advancing through scientific endeavors.
